AI is no longer just a tool in drug discovery; it's becoming a scientific collaborator that works alongside researchers to design experiments, interpret data, and generate hypotheses at speeds that were unimaginable just a few years ago. A comprehensive analysis of the AI and biotech startup landscape reveals that more than 120 companies are now building intelligent systems that fundamentally reshape how drugs are discovered, developed, and brought to market. Rather than replacing scientists, these platforms are augmenting their capabilities, shifting researchers away from tedious manual work toward higher-level strategic thinking.

What Are AI Co-Scientists, and How Do They Work?

AI co-scientists represent a new category of intelligent, agent-based platforms that automate or augment large portions of the scientific process. Unlike simple chatbots that answer questions, these systems function as integrated research partners, combining reasoning models with tool orchestration, data integration, and workflow automation to run complete research cycles from start to finish. They handle everything from hypothesis generation and literature review to experiment design, execution, and analysis. The key advantage is that they institutionalize knowledge, meaning they capture and compound organizational scientific knowledge across the entire discovery lifecycle, enabling faster iteration and smarter decision-making.

Companies building these platforms include DaltonTx, Kiin Bio, Coincidence Labs, Phylo, Potato, Edison Scientific, GXL, Science Machine, and Causaly. These startups are essentially creating digital lab partners that can reason about complex biological problems and guide scientists toward the most promising research directions.

How Are Startups Solving the AI Accessibility Bottleneck for Biologists?

As the number of biological AI models has exploded, a critical bottleneck has emerged: most bench scientists cannot use these advanced tools without specialized machine learning engineering support, GPU provisioning, and custom data pipelines. This gap between cutting-edge AI and practical usability is being addressed by a new wave of infrastructure companies that democratize access to these powerful models.

• No-Code Model Hosting: Tamarind Bio hosts over 200 open-source and community models, including AlphaFold and RFdiffusion, in a cloud platform that requires no coding expertise, making advanced protein structure prediction and molecular design accessible to biologists without ML backgrounds.
• Unified Foundation Model Frameworks: Helical provides both a unified framework for working with biological foundation models and its own pre-trained models, offering a Virtual Lab for biologists and a Model Factory for machine learning engineers to customize and fine-tune models on proprietary data.
• Multi-Model Orchestration: Salt AI provides a platform to deploy, build, optimize, and run multi-model systems for drug discovery workflows, allowing researchers to combine different AI models to solve complex problems.

What Does the Lab of the Future Look Like?

The pharmaceutical laboratory is undergoing a profound transformation. The lab of the future is increasingly autonomous, software-defined, and deeply integrated with AI, where scientists describe their goals and intelligent systems design, run, and iterate experiments end-to-end without manual intervention. This shift is being enabled by platforms that translate natural language into executable lab protocols and by fully automated systems that physically synthesize and test compounds at scale.

Companies like b12 and Briefly are translating natural-language instructions into executable protocols across connected lab hardware, while Adaptyv Bio and OnePot AI provide cloud or automated labs that physically synthesize and test proteins or small molecules at speed, feeding high-quality experimental data back into AI models to improve future predictions. Instance Bio and Dash Bio represent the digitized backbone of this ecosystem, turning experimental and clinical workflows into fully automated, data-rich pipelines that accelerate bioanalysis and drug development.

In manufacturing and process development, Reactwise applies Bayesian optimization and pre-trained chemistry models to cut up to 95 percent of experimental work in chemical scale-up by integrating with robotic lab systems. Differential Bio combines robotic lab automation with mechanistic and data-driven AI models to optimize bioproduction scale-up, tackling manufacturability bottlenecks in fermentation and microbial cell culture. Companies like Lila are pushing toward "self-driving" science, where systems generate hypotheses, run experiments, and learn in real time, while Medra emphasizes "continuous science" platforms that tightly couple AI reasoning with robotic execution, creating closed-loop systems that can design, run, and learn from experiments autonomously at scale.

How Is AI Catching Drug Safety Problems Earlier?

Over 30 percent of clinical candidates fail due to toxicity that could, in principle, have been caught earlier in development. A new generation of startups is using AI to predict and test drug safety across different layers of the development stack, potentially saving years of development time and millions of dollars. Axiom focuses on mechanistic reasoning to reveal a drug's full risk profile and uncover the biological mechanisms that drive toxicity, enabling better decision-making. Sable Bio automates target safety assessments using large language models and causal inference, compressing work that traditionally takes toxicologists weeks into just hours.

Inductive Bio predicts ADMET properties (absorption, distribution, metabolism, excretion, and toxicity) using models trained on a pre-competitive data consortium that pools proprietary experimental data across multiple pharma partners, and is developing AI drug toxicity models that improve drug safety assessment. Quris AI takes a different approach, combining stem cell-derived organ-on-chip systems with machine learning to functionally test drug candidates on miniaturized human tissue at scale, predicting drug safety before expensive clinical trials begin.

What Role Are Virtual Patients Playing in Drug Development?

Virtual patient solutions represent another frontier in AI-driven drug discovery. These are AI-driven platforms that simulate how individual patients or cohorts will respond to therapies by modeling biology across multiple scales, from molecular pathways to whole-organism and population dynamics. Moving beyond correlation-based machine learning, these systems integrate multi-modal data such as genomics, clinical records, and imaging to reason about biology, enabling granular prediction of clinical endpoints, adverse events, and treatment efficacy before real-world trials begin.

Startups building these platforms include Ingenix, Bioptimus, Quant Health, Synthesize Bio, Valinor, and Atlas Bio. These tools allow teams to design and test trials in silico, optimize patient selection, identify responder subgroups, and de-risk development. Theremia leverages real-world patient datasets and AI simulations to optimize drug dosing, formulation, and efficacy across subpopulations, particularly in central nervous system diseases. Parallel Bio takes a biological-meets-AI approach, growing human lymph node organoids that replicate immune responses across diverse patient populations to run "clinical trials in a dish," testing drug candidates on miniaturized human tissue.

How Are Large Pharma Companies Deploying Agentic AI at Scale?

While startups are innovating at the edges, large pharmaceutical companies are making bold moves to embed AI deeply into their operations. In May 2026, Bristol Myers Squibb announced a landmark strategic partnership with Anthropic to deploy Claude Enterprise, an agentic AI platform, across its global operations. This initiative equips more than 30,000 BMS employees, essentially the entire company, with advanced AI capabilities to accelerate drug discovery, development, manufacturing, and commercial activities.

"The companies that lead the next decade of biopharma will be the ones that learn to operate fundamentally differently with AI," stated Greg Meyers, Chief Digital and Technology Officer at BMS.

Greg Meyers, Chief Digital and Technology Officer at Bristol Myers Squibb

BMS characterizes this deployment as the "shared intelligence platform" of its company, moving beyond simple chatbots toward AI agents embedded within daily workflows. The rollout combines Claude, a frontier language model with agentic features, and Claude Code, a coding assistant to unify software and data engineering. The collaboration aims to unlock the vast trove of BMS's proprietary data, including scientific literature, clinical records, regulatory documents, and manufacturing logs, by integrating Claude across research, clinical development, manufacturing quality, and commercial functions.

This is among the largest pharmaceutical industry AI rollouts, paralleling other major initiatives such as Merck's April 2026 partnership with Google Cloud, which equipped 75,000 employees, and collaborations between Novo Nordisk and OpenAI and between Lilly and NVIDIA. BMS's Chief Digital and Technology Officer emphasized that traditional enterprise AI "stops at the chatbot" and that true value lies in breaking data silos with agentic AI that "connects every BMS employee" to institutional knowledge.

What Challenges Must Pharma Companies Overcome to Make AI Work?

Deploying AI at enterprise scale entails far more than technical integration. It requires organizational and cultural shifts that many companies struggle to execute. Simply deploying AI tools does not automatically yield value; companies must define a clear vision, build trust through data governance, reconfigure workflows, restructure organizations, and empower employees as change agents. Real-world precedents illustrate both the potential and the pitfalls. AstraZeneca reportedly halved discovery timelines with AI, Formation Bio cut trial times by 50 percent, and McKinsey estimates 35 to 45 percent productivity gains in clinical development. However, historical analysis suggests most enterprise AI pilots fail without strategic focus, so BMS's approach underscores the importance of clarity, governance, and employee engagement.

The pharmaceutical industry's transformation is accelerating. With over 120 startups innovating across AI co-scientists, autonomous labs, drug safety prediction, and virtual patients, combined with major pharma companies deploying agentic AI at scale, the future of drug discovery is becoming increasingly intelligent, collaborative, and data-driven. The winners will be those that successfully integrate AI not as a tool, but as a fundamental partner in the scientific process.